| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $3K | — | -84.2% |
| SG&A Expense | $1.3M | — | -29.5% |
| Operating Income | -$1.3M | — | +30.0% |
| Net Income | -$1.2M | — | +35.2% |
| EPS (Basic) | -$0.32 | — | -164.0% |
| EPS (Diluted) | -$0.32 | — | -164.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.3M | -18.7% | -56.9% |
| Current Assets | $4.5M | +8.7% | -44.2% |
| Total Assets | $4.5M | +8.6% | -44.2% |
| Current Liabilities | $905K | +175.1% | +0.2% |
| Total Liabilities | $905K | +175.1% | +0.1% |
| Stockholders' Equity | $3.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.1M | — | +41.1% |
| Financing Cash Flow | $1.0M | — | — |
| -49.8% |